| A phase I combination study of olaparib with cisplatin and gemcitabine in adults with solid tumors A Rajan, CA Carter, RJ Kelly, M Gutierrez, S Kummar, E Szabo, ... Clinical cancer research 18 (8), 2344-2351, 2012 | 188 | 2012 |
| Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer YM Ning, JL Gulley, PM Arlen, S Woo, SM Steinberg, JJ Wright, ... Journal of clinical oncology 28 (12), 2070, 2010 | 177 | 2010 |
| Scaling pharmacodynamics from in vitro and preclinical animal studies to humans DE Mager, S Woo, WJ Jusko Drug metabolism and pharmacokinetics 24 (1), 16-24, 2009 | 151 | 2009 |
| Population pharmacokinetic analysis of sorafenib in patients with solid tumours L Jain, S Woo, ER Gardner, WL Dahut, EC Kohn, S Kummar, DR Mould, ... British journal of clinical pharmacology 72 (2), 294-305, 2011 | 145 | 2011 |
| Safety and feasibility of long-term intravenous sodium nitrite infusion in healthy volunteers RM Pluta, EH Oldfield, KD Bakhtian, AR Fathi, RK Smith, HL DeVroom, ... PloS one 6 (1), e14504, 2011 | 142 | 2011 |
| Sorafenib is an inhibitor of UGT1A1 but is metabolized by UGT1A9: implications of genetic variants on pharmacokinetics and hyperbilirubinemia CJ Peer, TM Sissung, AR Kim, L Jain, S Woo, ER Gardner, CT Kirkland, ... Clinical cancer research 18 (7), 2099-2107, 2012 | 132 | 2012 |
| Far-red light-activatable prodrug of paclitaxel for the combined effects of photodynamic therapy and site-specific paclitaxel chemotherapy P Thapa, M Li, M Bio, P Rajaputra, G Nkepang, Y Sun, S Woo, Y You Journal of medicinal chemistry 59 (7), 3204-3214, 2016 | 110 | 2016 |
| Pharmacokinetic and pharmacodynamic modeling of the antiplatelet and cardiovascular effects of cilostazol in healthy humans SK Woo, WK Kang, K Kwon Clinical Pharmacology & Therapeutics 71 (4), 246-252, 2002 | 105 | 2002 |
| Interspecies comparisons of pharmacokinetics and pharmacodynamics of recombinant human erythropoietin S Woo, WJ Jusko Drug metabolism and disposition 35 (9), 1672-1678, 2007 | 86 | 2007 |
| Population pharmacokinetics of romidepsin in patients with cutaneous T-cell lymphoma and relapsed peripheral T-cell lymphoma S Woo, ER Gardner, X Chen, SB Ockers, CE Baum, TM Sissung, DK Price, ... Clinical cancer research 15 (4), 1496-1503, 2009 | 82 | 2009 |
| Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after intravenous and subcutaneous administration in rats S Woo, W Krzyzanski, WJ Jusko Journal of Pharmacology and Experimental Therapeutics 319 (3), 1297-1306, 2006 | 80 | 2006 |
| Target-mediated pharmacokinetic and pharmacodynamic model of recombinant human erythropoietin (rHuEPO) S Woo, W Krzyzanski, WJ Jusko Journal of pharmacokinetics and pharmacodynamics 34, 849-868, 2007 | 78 | 2007 |
| Exosome is a mechanism of intercellular drug transfer: Application of quantitative pharmacology J Wang, BZ Yeung, M Cui, CJ Peer, Z Lu, WD Figg, MG Wientjes, S Woo, ... Journal of Controlled Release 268, 147-158, 2017 | 69 | 2017 |
| Phase I trial of a new schedule of romidepsin in patients with advanced cancers L Amiri-Kordestani, V Luchenko, CJ Peer, K Ghafourian, J Reynolds, ... Clinical Cancer Research 19 (16), 4499-4507, 2013 | 67 | 2013 |
| Pharmacodynamic model for chemotherapy-induced anemia in rats S Woo, W Krzyzanski, WJ Jusko Cancer chemotherapy and pharmacology 62, 123-133, 2008 | 63 | 2008 |
| Phase I study of oral lenalidomide in patients with refractory metastatic cancer WL Dahut, JB Aragon‐Ching, S Woo, TM Tohnya, JL Gulley, PM Arlen, ... The Journal of Clinical Pharmacology 49 (6), 650-660, 2009 | 59 | 2009 |
| CXCR2 inhibition combined with sorafenib improved antitumor and antiangiogenic response in preclinical models of ovarian cancer B Devapatla, A Sharma, S Woo PLoS One 10 (9), e0139237, 2015 | 57 | 2015 |
| Pharmacodynamic models for agents that alter production of natural cells with various distributions of lifespans W Krzyzanski, S Woo, WJ Jusko Journal of pharmacokinetics and pharmacodynamics 33, 125-166, 2006 | 50 | 2006 |
| Population pharmacokinetics and pharmacodynamics of brief etomidate infusion in healthy volunteers K Kaneda, S Yamashita, S Woo, TH Han The Journal of Clinical Pharmacology 51 (4), 482-491, 2011 | 42 | 2011 |
| Folate-PEG conjugates of a far-red light-activatable paclitaxel prodrug to improve selectivity toward folate receptor-positive cancer cells P Thapa, M Li, R Karki, M Bio, P Rajaputra, G Nkepang, S Woo, Y You ACS omega 2 (10), 6349-6360, 2017 | 40 | 2017 |
You, YoungjaeUniversity at Buffalo, SUNYVerified email at buffalo.edu
